Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Fallopian Tube Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P3	CCC (52)
Sacituzumab Tirumotecan Breast Neoplasm	Merck Sharp & Dohme LLC	P3	CCC (52)
Sacituzumab Tirumotecan Fallopian Tube Cancer	Merck Sharp & Dohme LLC	P3	CCC (52)
Trastuzumab Pamirtecan HER2 Positive Breast Carcinoma	DualityBio Inc.	P3	CCC (52)
Datopotamab Deruxtecan Endometrial Carcinoma	AstraZeneca	P2	CCC (52)
Datopotamab Deruxtecan Gastric Cancer	AstraZeneca	P2	CCC (52)
hlx43 Non-Small Cell Lung Carcinoma	Shanghai Henlius Biotech	P2	CCC (52)
Ifinatamab Deruxtecan Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (52)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Esophageal Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (52)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Head And Neck Squamous Cell Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (52)
Loncastuximab Tesirine High Grade B-Cell Lymphoma	Universität Münster	P2	CCC (52)
Loncastuximab Tesirine Mantle Cell Lymphoma	University of Washington	P2	CCC (52)
Polatuzumab Vedotin Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Christine Ryan	P2	CCC (52)
Polatuzumab Vedotin Hodgkins Lymphoma	M.D. Anderson Cancer Center	P2	CCC (52)
rc108 Non-Small Cell Lung Carcinoma	RemeGen Co., Ltd.	P2	CCC (52)
rc48-adc Colorectal Cancer Metastatic	Anbogen Therapeutics, Inc.	P2	CCC (52)
rc48-adc Lymphoma	Won Seog Kim	P2	CCC (52)
rc48-adc Solid Tumor, Adult	Fudan University	P2	CCC (52)
Sacituzumab Tirumotecan Lung Cancer	Merck Sharp & Dohme LLC	P2	CCC (52)
Sacituzumab Tirumotecan Pancreatic Ductal Adenocarcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (52)
Trastuzumab Deruxtecan Her2-Receptor Negative Breast Cancer	Kristina A. Fanucci	P2	CCC (52)
Trastuzumab Duocarmazine HER2 Positive Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (52)
Trastuzumab Emtansine Melanoma	Ascendis Pharma Oncology Division A/S	P2	CCC (52)
Trastuzumab Emtansine Metastatic Solid Tumor	M.D. Anderson Cancer Center	P2	CCC (52)
Trastuzumab Emtansine Triple Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (52)

Showing 526 to 550 of 1,027 assets

PreviousPage 22 of 42Next